Literature DB >> 3718596

Pharmacokinetics of glucosamine in the dog and in man.

I Setnikar, C Giacchetti, G Zanolo.   

Abstract

The pharmacokinetics, organ distribution, metabolism and excretion of glucosamine were studied in the dog giving uniformly labelled [14C]-glucosamine (sulfate), i.v. or orally, in single doses. Immediately after i.v. administration, the radioactivity in plasma is due to glucosamine, and freely diffuses into organs and tissues. This radioactivity disappears quickly from plasma (initial t1/2 = 13 min, terminal t1/2 = 118 min). After 30-60 min the radioactivity in plasma is no longer due to glucosamine, but is incorporated into alpha- and beta-globulins. The protein-incorporated radioactivity is found already 20-30 min after i.v. administration, reaches a peak after 8 h and then slowly disappears, with a t1/2 = 2.9 days. Of the administered radioactivity, more than 34% is excreted in the urine, mainly as glucosamine, and 1.7% is excreted in the feces. Radioactivity is excreted also as [14C]-CO2 in the expired air. The radioactivity, after i.v. administration, diffuses rapidly from blood into the body. Some organs show an active uptake of radioactivity, e.g. the liver and the kidney. Other tissues, such as the articular cartilage, also have an active uptake. In most other organs the radioactivity found can be explained by passive diffusion processes from plasma. After oral administration of a single dose of [14C]-glucosamine the radioactivity is quickly and almost completely absorbed from the gastrointestinal tract. The pattern of disappearance, metabolic transformation, tissue distribution and excretion of the radioactivity are consistent with those found after i.v. administration.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718596

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  11 in total

1.  Glucosamine for osteoarthritis. Patients' welfare should be primary concern.

Authors:  D Sonnino
Journal:  BMJ       Date:  2001-10-27

2.  Effect of longeing and glucosamine supplementation on serum markers of bone and joint metabolism in yearling quarter horses.

Authors:  J I Fenton; M W Orth; K A Chlebek-Brown; B D Nielsen; C D Corn; K S Waite; J P Caron
Journal:  Can J Vet Res       Date:  1999-10       Impact factor: 1.310

Review 3.  The use of glucosamine therapy in osteoarthritis.

Authors:  Djamila Zerkak; Maxime Dougados
Journal:  Curr Pain Headache Rep       Date:  2004-12

4.  Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness.

Authors:  B A Biggee; C M Blinn; T E McAlindon; M Nuite; J E Silbert
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

Review 5.  Glucosamine: a review of its use in the management of osteoarthritis.

Authors:  Anna J Matheson; Caroline M Perry
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 6.  The use of glucosamine therapy in osteoarthritis.

Authors:  Djamila Zerkak; Maxime Dougados
Journal:  Curr Rheumatol Rep       Date:  2004-02       Impact factor: 4.592

7.  Dietary glucosamine under question.

Authors:  Jeremiah E Silbert
Journal:  Glycobiology       Date:  2009-03-02       Impact factor: 4.313

8.  Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine.

Authors:  Nina Ivanovska; Petya Dimitrova
Journal:  Arthritis Res Ther       Date:  2011-03-16       Impact factor: 5.156

9.  Effect of fucoidan extracted from mozuku on experimental cartilaginous tissue injury.

Authors:  Tomohiro Osaki; Koudai Kitahara; Yoshiharu Okamoto; Tomohiro Imagawa; Takeshi Tsuka; Yasunari Miki; Hitoshi Kawamoto; Hiroyuki Saimoto; Saburo Minami
Journal:  Mar Drugs       Date:  2012-11-13       Impact factor: 5.118

10.  A clinical study on glucosamine sulfate versus combination of glucosamine sulfate and NSAIDs in mild to moderate knee osteoarthritis.

Authors:  Tamil Selvan; Kingston Rajiah; M Sundara-Moorthi Nainar; Elizabeth M Mathew
Journal:  ScientificWorldJournal       Date:  2012-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.